ADCT

1.2801.54%
AM

Ameet Mallik

CEO & Director

Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He had been a Director of Atara Biotherapeutics, Inc. since August 2021 until September 2025. Dr. Mallik serves as Chief Executive Officer at ADC Therapeutics SA since 2022. He served as Business Advisor of Juvena Therapeutics, Inc until 2026. Dr. Mallik served as Chief Executive Officer and President at ADC Therapeutics SA since May 2022 until 2022. Dr. Mallik served as Non-Executive Chairman at Rafael Pharmaceuticals, Inc. until 2022. He served as Chief Executive Officer of Rafael Holdings, Inc., since May 1, 2021 until February 1, 2022 and served as Director since June 2021 until May 29, 2022. Dr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial leadership roles at Novartis and Sandoz. At Sandoz, Dr. Mallik was Head of Biopharmaceuticals & Oncology Injectables at Sandoz. Dr. Mallik previously worked as an Associate Principal at McKinsey and Company. Dr. Mallik served as Executive Vice President and Head, U.S. Oncology of Novartis from November 2017 to April 2021. He served as an Executive Vice President and Head of U.S. Oncology at Novartis AG until May 1, 2021 and was responsible for commercial and medical operations in the United States. He served as Head of Biopharmaceuticals and Oncology Injectables at Sandoz Inc. Dr. Mallik served Head of Latin America and Canada for Novartis Oncology from April 2014 to November 2015. Dr. Mallik served as Head of Global Marketing, Value and Access at Novartis Oncology from November 2015 to November 2017. He served as Global Head of Biopharmaceuticals and Oncology Injectables at Sandoz International GmbH since August 2009. He joined Sandoz as Head Biopharmaceuticals in August 2009. He joined Novartis Pharma in 2005 and served as the Head of Global Strategic Planning. He worked at McKinsey & Company in the US. He started his career at Abbott Labs in the US, holding roles in engineering and business development. A US national. He served as Brand Director of Tekturna at Novartis Pharma in the US. He graduated with a BSc in Chemical Engineering and an MSc in Biotechnology from Northwestern University, US. Dr. Mallik holds an MBA from the Wharton School at the University of Pennsylvania, US.

Positions